
JnJ seeks USFDA nod of Stelara for pediatric Crohn's disease
Horsham: Johnson & Johnson is seeking the U.S. Food and Drug Administration (FDA) approval for the expansion of STELARA (ustekinumab) for the treatment of children two years and older with moderately to severely active Crohn’s disease (CD). The company …